News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Publication

Article

July 6, 2023

Pharmaceutical Executive

Pharmaceutical Executive: July 2023
Volume43
Issue 7

Shifting Macro Trends Offer Hope for Biotech Performance Boost

Author(s):

Barbara Ryan

But will Washington’s dealmaking stance upend the momentum?

Barabara Ryan

For the first time since January 2022, the Fed did not raise interest rates at its latest meeting, halting a streak of 10 straight previous hikes and putting at least a pause on the most rapid Fed-induced rise in interest rates in history. That is great news for rate-sensitive biotech stocks. The prolonged and unrelenting string of rate hikes was the No. 1 enemy of biotech valuations, which—as the longest dated of assets—trade inversely with rates. While the market is not wholly convinced that we have seen the last Fed rate hike, it does appear to be looking ahead to a potential for future rate cuts due to a slowdown in inflation, economic growth, rising unemployment, and (potentially) a recession.

This Fed pivot is a major positive shift in the macro climate in favor of biotech. Combined with continued solid momentum in M&A, it has fueled more than a 20% rally off the year-to-date lows as investors rotate back into growth from value. To be expected, capital markets activity has picked up with a healthy flow of follow-on offerings. According to data from SVB Securities, the largest participants, not surprisingly, are the biotech-dedicated investors who have been the biggest winners in M&A trades this year. If sector performance continues to be positive, other life sciences funds will seek out alpha here as will the long-departed generalist investors.

The number of companies in the sector trading below cash is also now declining with the valuation correction, positive datasets, and newfound discipline behind spending, program prioritization, and consolidation.

M&A tailwind remains a reason for optimism

Large pharma is flush with cash and—according to EY’s most recent annual Firepower report—they have more than $1.4 trillion to fund M&A, strategic partnerships, and collaborations. M&A has always been a core pillar of leading companies’ growth strategies, and emerging biotech innovators are their targets. The need has never been greater. In addition, they will face LOEs for products with revenues exceeding $300 billion, beginning in 2025. I expect a strong year of M&A and dealmaking in 2023.

My colleague, Tim Opler of Stifel, says of this year’s M&A activity: “It’s a ‘blistering’ pace on track for $300 billion by year’s end, which could approach an all-time deal record of $328 billion in 2019.” These metrics are according to his firm’s research.

While macro factors may be shifting from headwinds to tailwinds, there are industry-specific storm clouds overhead fueling uncertainty that could threaten short- and long-term fundamentals. Companies and investors will have to monitor these closely.

In a Financial Times article titled “Big Pharma Dealmaking Recovers with $85bn M&A Splurge,” Jamie Smyth talks about M&A trends and the potentially chilling effect of the Federal Trade Commission’s Amgen-Horizon Therapeutics merger suit on biopharmaceutical innovation. Smyth cites Paul Hastings, chief executive of Nkarta, an early-stage biotech company, and an outgoing chair of BIO, the biotech industries’ main lobbying group. Hastings warns “that US antitrust authorities’ tougher stance on pharma/biotech deals risks upending a decades-long business model that underpins innovation. This model attracts investors to biotechs that are pursuing high-risk research in the knowledge that large companies may later buy them and supply the funds needed to complete expensive clinical trials and [commercialize] new drugs.” Smyth also adds that, in the past two decades, small- to mid-sized biotechs have grown in importance to drug development.

The Inflation Reduction Act (IRA), passed in August of 2022, gave Medicare the power to lower prices on certain top-selling drugs that have no competition—starting with 10 medicines in 2026. But the details of the process were left to the US Department of Health and Human Services (HHS) to work out, and it has since released initial guidance and a timeline that will name the first set of drugs up for negotiation by Sept. 1. In addition, the US Chamber of Commerce, Merck, and Bristol Myers Squibb are suing HHS over the IRA, arguing that is unconstitutional.

I believe it’s true that fundamentals for many across our industry are strong, innovation is alive and well, and M&A is—and always has been—a core pillar of the growth strategies for the largest companies; and there is more money to fund it than ever. Biopharma has always been a growth industry, and I don’t believe that has changed or will. There is a lot of money earmarked to be invested behind good data, and patients will be the ultimate beneficiary of the substantive advances our industry continues to deliver.

Download Issue PDF
Articles in this issue

Pharm Exec roundtable
The AI Revolution Has Arrived: Shaping the Next Generation of Pharma Marketing
Kabir Nath
Crossing the Brain Barrier
Matthew Arnold
Biotech’s Survival Story: Companies Bear Down for Lean Years
Celeste Warren
DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles
Doron Aspitz
Harnessing AI for Pharma Sales
Bruce Liu
Tapping New and Improved Drug Innovations in Asia
Jill Wechsler
Drug Shortages Continue to Plague FDA, Manufacturers
EU flag
Contrasting Aims Highlight Pharma Reform Pursuits
Barabara Ryan
Shifting Macro Trends Offer Hope for Biotech Performance Boost
Ira Studin, PhD
‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk
Arda Ural, PhD
Navigating the Recession and Patent Expirations
Meg Rivers
Marketing in the AI Age
Mike Hennessy Jr
AI Heating Up On the Pharma Stage
Pharm Exec July 2023
Pharmaceutical Executive, July 2023 Issue (PDF)

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Fred Aslan
Related Content
Advertisement
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 1st 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Credit: zimmytws | stock.adobe.com. Balancing profitability with affordability, redesigning supply chains for resilience, and engaging actively in trade policy discussions are no longer optional, they are strategic imperatives.
August 1st 2025

How Can Pharma Leadership Prepare for the Current Tariff Environment and Potential Changes in 2026?

Thani Jambulingam, PhD
The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.
Moderna to Reduce Workforce by 10% Amid Cost Restructuring
August 1st 2025

Moderna to Reduce Workforce by 10% Amid Cost Restructuring

Don Tracy, Associate Editor
Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets $1.5 billion in savings by 2027.
Bausch Health Acquires DURECT Corporation in Deal Worth up to $413 Million
August 1st 2025

Bausch Health Acquires DURECT Corporation in Deal Worth up to $413 Million

Don Tracy, Associate Editor
The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio as the company advances its liver disease research and development efforts.
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital
August 1st 2025

Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital

Don Tracy, Associate Editor
The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from industry veterans.
Nordic Capital, Permira Reach Agreement to Acquire Bavarian Nordic in $3 Billion Deal
August 1st 2025

Nordic Capital, Permira Reach Agreement to Acquire Bavarian Nordic in $3 Billion Deal

Don Tracy, Associate Editor
Under terms of the deal, Bavarian Nordic shareholders will receive an all-cash offer at a premium, with plans to delist the company and accelerate its global vaccine strategy.
Related Content
Advertisement
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 1st 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Credit: zimmytws | stock.adobe.com. Balancing profitability with affordability, redesigning supply chains for resilience, and engaging actively in trade policy discussions are no longer optional, they are strategic imperatives.
August 1st 2025

How Can Pharma Leadership Prepare for the Current Tariff Environment and Potential Changes in 2026?

Thani Jambulingam, PhD
The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.
Moderna to Reduce Workforce by 10% Amid Cost Restructuring
August 1st 2025

Moderna to Reduce Workforce by 10% Amid Cost Restructuring

Don Tracy, Associate Editor
Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets $1.5 billion in savings by 2027.
Bausch Health Acquires DURECT Corporation in Deal Worth up to $413 Million
August 1st 2025

Bausch Health Acquires DURECT Corporation in Deal Worth up to $413 Million

Don Tracy, Associate Editor
The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio as the company advances its liver disease research and development efforts.
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital
August 1st 2025

Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital

Don Tracy, Associate Editor
The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from industry veterans.
Nordic Capital, Permira Reach Agreement to Acquire Bavarian Nordic in $3 Billion Deal
August 1st 2025

Nordic Capital, Permira Reach Agreement to Acquire Bavarian Nordic in $3 Billion Deal

Don Tracy, Associate Editor
Under terms of the deal, Bavarian Nordic shareholders will receive an all-cash offer at a premium, with plans to delist the company and accelerate its global vaccine strategy.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.